![]() |
市场调查报告书
商品编码
2021512
精准发酵原料市场预测至2034年-按产品类型、原料、发酵製程、应用、最终用户及地区分類的全球分析Precision Fermentation Ingredients Market Forecasts to 2034 - Global Analysis By Product Type, Raw Material, Fermentation Process, Application, End User and By Geography |
||||||
根据 Stratistics MRC 的数据,预计到 2026 年,全球精细发酵原料市场规模将达到 38 亿美元,并在预测期内以 15.6% 的复合年增长率增长,到 2034 年将达到 122 亿美元。
精准发酵原料是指透过程式化调控酵母、细菌和丝状真菌等微生物宿主,并在商业规模的生物图器中进行发酵,从而表达特定目标分子,进而生产生物活性化合物、蛋白质、脂质、维生素、酵素、香料、色素和功能性纤维。这使得生产用于食品饮料、医药和化妆品领域的原料成为可能,这些原料在功能上与传统的动物源性或合成替代品完全相同,但无需使用动物性成分,且具有更高的土地利用效率。
对替代蛋白质的需求
食品生产商对非动物性功能性蛋白质的需求激增,他们希望找到性能与传统乳製品和鸡蛋媲美的产品,这加速了微发酵原料的商业化进程。像Perfect Day和Remilk这样的公司正在展示消费者认可的微发酵乳清蛋白和酪蛋白,这些产品可用于冰淇淋、优格和烘焙点心。品牌永续性计画和消费者对蛋白质多样化的偏好,也促使企业更加关注微发酵原料的供应。
新食品的监管核准
根据欧洲食品安全局 (EFSA) 和各国食品安全机构的监管框架,新食品产品需要经过漫长的核准,导致微发酵原料类产品上市时间延长数年。此类产品必须进行广泛的毒性测试并记录成分特征,这是新原料安全文件的强制性要求。这显着增加了原料註册成本,并将产品上市时间延长至Start-Ups公司资金筹措期之后。
医药级生产
药品和生物製药的生产应用代表高附加价值的成长机会。这是因为微发酵平台已展现出以与传统合成路线相媲美的成本和纯度生产药物活性成分、重组蛋白和稀有生物活性分子的能力。对发酵衍生治疗性蛋白质的生物製药契约製造需求正在催生高利润的生产合同,这有助于抵消双用途发酵设施营运商在食品原料规模化生产方面的投资。
消费者对基因改造生物的看法
消费者对微发酵生产流程与基因改造生物(GMO)之间关联的担忧,对市场接受度构成威胁,使得含有微发酵成分的食品的零售标籤策略和品牌定位变得复杂。儘管基因改造作物和发酵衍生成分在监管方面有所区别,但公众认知上的差异以及生物技术领域媒体报告的混乱,造成了品牌风险。因此,在微发酵成为主流食品应用之前,需要投入大量资金进行消费者教育,以克服这些风险。
新冠疫情暴露了传统动物性原料供应链的诸多脆弱性,加速了食品生产商对微发酵作为供应链韧性策略的兴趣。疫情期间可持续发展意识的增强以及投资者对替代食品技术的热情,扩大了微发酵领域的资金筹措和商业性伙伴关係。为实现后疫情时代食品体系转型而进行的投资,持续为微发酵原料在大众市场食品应用领域的商业化注入大量资金。
在预测期内,微发酵产生的风味和芳香化合物细分市场预计将成为最大的细分市场。
在预测期内,微发酵生产的风味和芳香化合物预计将占据最大的市场份额。这主要归功于现有食品法规结构内发酵风味化合物的商业性先例,以及目标芳香分子与传统天然风味萃取方法和合成风味合成方法相比所展现出的成本竞争力。随着品牌寻求能够标註为「天然来源」且供应链更清洁的风味成分,以取代传统萃取方法,领先的风味生产商正积极寻求微发酵供应伙伴关係。
在预测期内,微生物宿主生物体细分市场预计将呈现最高的复合年增长率。
在预测期内,微生物宿主生物体领域预计将呈现最高的成长速度。这主要得益于合成生物学工具包的扩展,这些工具包能够设计出具有更高产量、更广泛的基材可用性和更强的抗逆性的新型微生物底盘。这将降低发酵生产成本,并扩大目标原料类别的商业性可行性。对专有微生物菌株开发的投资正在带来竞争优势,这推动了精准发酵平台公司在研发方面的大量投入。
在预测期内,北美预计将占据最大的市场份额。这是因为美国拥有全球最成熟的精准发酵投资生态系统,孕育了 Perfect Day、Ginkgo Bioworks 和 Amyris 等主要企业。该生态系统得益于丰富的创业投资投资、联邦政府对生物经济研究的资助以及完善的食品技术监管管道,这些都为面向国内和出口市场的原材料商业化生产提供了支持。
在预测期内,亚太地区预计将呈现最高的复合年增长率。这主要得益于中国、印度和新加坡对替代蛋白需求的快速增长,而这种增长又受到都市化、蛋白质价格挑战以及政府粮食安全投资计划的推动;此外,国内精细发酵Start-Ups的活跃度不断提高,以及大型食品公司加大对区域消费品发酵衍生原料供应链伙伴关係的投资,也是推动亚太地区增长的主要因素。
According to Stratistics MRC, the Global Precision Fermentation Ingredients Market is accounted for $3.8 billion in 2026 and is expected to reach $12.2 billion by 2034 growing at a CAGR of 15.6% during the forecast period. Precision fermentation ingredients refer to bioactive compounds, proteins, fats, vitamins, enzymes, flavors, pigments, and functional fibers produced through the programmatic engineering of microbial host organisms including yeast, bacteria, and filamentous fungi to express specific target molecules from genetic blueprints using bioreactor fermentation processes at commercial scale, enabling animal-free and land-efficient production of ingredients functionally identical to conventional animal-derived or synthetic counterparts for food, beverage, pharmaceutical, and cosmetic applications.
Alternative Protein Demand
Surging alternative protein demand from food manufacturers seeking animal-free functional protein ingredients with conventional dairy and egg performance characteristics is accelerating precision fermentation ingredient commercial scale-up as companies including Perfect Day and Remilk demonstrate consumer-acceptable precision-fermented whey and casein proteins for ice cream, yogurt, and baked goods applications. Brand sustainability commitments and consumer protein diversification preferences are generating substantial enterprise procurement interest in precision fermentation supply agreements.
Regulatory Novel Food Approval
Regulatory novel food approval timelines under European EFSA and various national food safety authority frameworks create multi-year commercialization delays for precision fermentation ingredient categories entering markets where novel ingredient safety dossier requirements mandate extensive toxicological studies and compositional characterization documentation that substantially increase ingredient registration costs and extend market entry timelines beyond startup funding horizons.
Pharmaceutical Grade Production
Pharmaceutical and biotherapeutic production applications represent a premium-value growth opportunity as precision fermentation platforms demonstrate capabilities for producing active pharmaceutical ingredients, recombinant proteins, and rare bioactive molecules at costs and purities competitive with conventional synthesis routes. Biopharmaceutical contract manufacturing demand for fermentation-derived therapeutic proteins is generating high-margin production contracts that cross-subsidize food ingredient scale-up investments for dual-use fermentation facility operators.
Consumer GMO Perception
Consumer perception concerns about genetically modified organism associations with precision fermentation production processes represent a market acceptance threat that complicates retail labeling strategies and brand positioning for food products containing precision-fermented ingredients. Despite regulatory distinctions between GMO crops and fermentation-derived ingredients, public awareness gaps and media conflation of biotechnology categories create brand risk that requires significant consumer education investment to overcome for mainstream food applications.
COVID-19 demonstrated critical vulnerabilities in conventional animal-derived ingredient supply chains that accelerated food manufacturer interest in precision fermentation as a supply chain resilience strategy. Pandemic-era sustainability awareness and investor enthusiasm for food technology alternatives elevated precision fermentation funding and commercial partnerships. Post-pandemic food system transformation investment continues to channel substantial capital toward precision fermentation ingredient commercialization for mass market food applications.
The precision-fermented flavors & aroma compounds segment is expected to be the largest during the forecast period
The precision-fermented flavors & aroma compounds segment is expected to account for the largest market share during the forecast period, due to established commercial precedent for fermentation-derived flavor compounds within existing food regulatory frameworks and demonstrated cost competitiveness with conventional natural flavor extraction and synthetic flavor synthesis routes for target aroma molecules. Major flavor houses are actively sourcing precision fermentation supply partnerships as brands seek natural-positioned flavor ingredients with cleaner supply chain documentation than conventional extraction alternatives.
The microbial host organisms segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the microbial host organisms segment is predicted to witness the highest growth rate, driven by expanding synthetic biology toolkits enabling engineering of novel microbial chassis with enhanced production yields, broader substrate utilization, and improved stress tolerance characteristics that reduce fermentation production costs and expand the commercial feasibility of target ingredient categories. Investment in proprietary microbial strain development is creating competitive advantages that drive significant R&D expenditure among precision fermentation platform companies.
During the forecast period, the North America region is expected to hold the largest market share, due to the United States hosting the world's most mature precision fermentation investment ecosystem with leading companies including Perfect Day, Ginkgo Bioworks, and Amyris, supported by strong venture capital availability, federal bioeconomy research funding, and established food technology regulatory pathways that enable commercial scale ingredient production for domestic and export markets.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly growing alternative protein demand in China, India, and Singapore driven by urbanization, protein affordability challenges, and government food security investment programs, combined with increasing domestic precision fermentation startup activity and major food company investment in fermentation-derived ingredient supply chain partnerships for regional consumer goods applications.
Key players in the market
Some of the key players in Precision Fermentation Ingredients Market include Perfect Day, Remilk, New Wave Foods, Motif FoodWorks, Change Foods, Imagindairy, Formo, Bond Pet Foods, MycoTechnology, Ginkgo Bioworks, Zymergen (Ginkgo), Amyris, Bolt Threads, Modern Meadow, Melt&Marble, and Nourish Ingredients.
In February 2026, Perfect Day secured a major supply agreement with a leading global ice cream manufacturer to provide precision-fermented whey protein for animal-free dairy product reformulation across European markets.
In January 2026, Amyris expanded its precision fermentation ingredient portfolio with commercial-scale production of fermentation-derived squalene for cosmetics and pharmaceutical applications, reducing dependency on shark liver oil sourcing.
In November 2025, Formo received European novel food approval for its precision-fermented casein protein, enabling commercial launch of animal-free European-style cheeses through specialty food retail distribution channels.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.